The EPS projection of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for quarter ended 2016-09-30 is $0.18. A week before, the EPS forecast was $0.18 against target of $0.18, a month earlier. This estimate stood at $0.18 60 days earlier versus forecast of $0.18 90 days earlier, confirming a deviation of 0%.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) reported that 18 days ago, the positive EPS revisions were 0 and negative revisions at 2.
In last week, the per-share earnings was lowered 0 times and 0 times positively. In last 120, 60, 30 and 90 days the positive revisions were 1, 3, 0 and 3, respectively.
The downgrade of EPS estimates for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the preceding 120, 60, 30 and 90 days were 2, 2, 0 and 2, in that order.
As per the latest update, for the quarter closed 1, the EPS estimate of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) was $0.18. This projection was computed after accounting 5 calls. As reported on 2016-05-03 the EPS was $0.08. The change was $0, demonstrating a percentage deviation of 0%. The projections confirmed a standard deviation of 0.02.
Quarterly Sales Estimates
For the fiscal 2016, the yearly sales target for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) stands at $59.89 and the median estimate at $59.155. Almost 4 analysts announced their estimates.
The highest estimate is $63.8 while the lowest target is $57.45 showing standard deviation of 2.863%.
As many as 4 analysts released sales estimates reised in upside while 4 reduced sales estimates, demonstrating a deviation of 0%.
In last month, 4 revised sales number projection on upside while 4 lowered the sales target, demonstrating a deviation of 0%.
A quarter ago, 4 hiked sales estimations and 4 reduced sales forecast. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) stated that the change in forecast was -0.321%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...